Send feedback

MAP2K2 p.Asp151=

c.453C>T · rs17851657 · VCV46237

Benign Expert panel
Classification
Benign
ClinVar
Review
Expert panel ★★★☆
ClinVar · 15 submitters
gnomAD v4.1
Common
common (popmax 21.5%, mid) — too common for a highly-penetrant pathogenic allele
Conditions
2
RASopathy

ClinGen expert panel — RASopathy VCEP

Benign for RASopathy. Applied ACMG criteria (verbatim):

BA1

Curation rationale (ClinGen, verbatim)

The filtering allele frequency of the c.453C>T (p.Asp151=) variant in the MAP2K2 gene is 27.128% (10569/38338) of European chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
Missense predictors do not apply to this variant type; conservation carries the signal.
Splicing
SpliceAI<0.2all four deltas below 0.2 · G>T here scores Δ0.54 · evaluated, not missing
Constraint at this position
ConservationphyloP -7.2GERP -3.5
Overall
CADD0.241PHRED · no single calibrated threshold — expert panels disagree

Population frequency

gnomAD v4.1 · exomes + genomes
Grpmax group 21.5% Middle Eastern · 1,297/6,034 alleles
Filtering AF 20.5% ClinGen BA1/BS1 input FAF95, joint · FAF99 20.4%
Overall 18.4% 293,088/1,595,462 alleles · common exomes 271,555/1,443,232 · genomes 21,533/152,230 · joint denominator
Ancestry group Frequency 1 in
Ashkenazi Jewishnot grpmax-eligible 22.1% 5
Middle Easterngrpmax 21.5% 5
South Asian 20.8% 5
European (non-Finnish) 19.9% 5
Amishnot grpmax-eligible 19.5% 5
Finnishnot grpmax-eligible 18.4% 5
Remaining individualsnot grpmax-eligible 17.4% 6
Admixed American 10.2% 10
East Asian 5.19% 19
African / African-American 4.22% 24

Ashkenazi Jewish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene
MAP2K2
Protein
p.Asp151=
Coding
c.453C>T
MANE Select
NM_030662
dbSNP
rs17851657
Type
single nucleotide variant
Location
chr19:4102451 (GRCh38)
Gene constraint
LOEUF 0.858 · pLI <0.01 (gnomAD)
Structure
AlphaFold pLDDT 82.54 · 3 PDB
Residue 151
the protein kinase domain
Full MAP2K2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/map2k2-p-asp151 (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown